Wave Life Sciences director proposes $64.1K sale

Accepted by SEC EDGAR 08/12/2026 - 04:32 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Wave Life Sciences Ltd. (WVE) director Adrian G. Rawcliffe reported a proposed sale of 12,700 common shares, with an approximate sale date of August 12, 2026.

The notice gives an aggregate market value of $64,071.50 and lists 197,048,175 common shares outstanding. It records March 6, 2026 as the date of plan adoption or instruction, if relying on Rule 10b5-1.

Key Figures

Common shares proposed for sale: 12,700 shares Aggregate market value: $64,071.50 Common shares outstanding: 197,048,175 shares +2 more

5 metrics

Common shares proposed for sale 12,700 shares Approximate sale date August 12, 2026

Aggregate market value $64,071.50 Proposed sale

Common shares outstanding 197,048,175 shares As listed in the sale notice

Plan adoption or instruction date March 6, 2026 If relying on Rule 10b5-1

Restricted stock units acquired 12,700 units Acquired from the issuer on August 11, 2026

Key Terms

Restricted Stock Units, Rule 10b5-1

2 terms

Restricted Stock Units financial

"Nature of Acquisition Transaction: Restricted Stock Units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Rule 10b5-1 regulatory

"If Relying on Rule 10b5-1"

Rule 10b5-1 is a regulation that allows company insiders to buy or sell their shares at predetermined times, even if they have access to non-public information. It acts like setting a schedule in advance for transactions, helping prevent accusations of unfair trading. This rule provides a way for insiders to plan trades transparently, giving investors confidence that these transactions are not based on hidden information.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many WVE shares does Adrian G. Rawcliffe plan to sell?

Adrian G. Rawcliffe reported a proposed sale of 12,700 common shares, with an approximate sale date of August 12, 2026 and an aggregate market value of $64,071.50.

How did Adrian G. Rawcliffe acquire the shares in the WVE sale notice?

The notice says 12,700 common shares were acquired from the issuer as restricted stock units on August 11, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001555851
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	WAVE LIFE SCIENCES INC
SEC File Number	001-37627
Address of Issuer	733 Concord Avenue Cambridge UNITED STATES 02138
Phone	617-949-2900
Name of Person for Whose Account the Securities are To Be Sold	ADRIAN G RAWCLIFFE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	12700	64071.50	197048175	08/12/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/11/2026	Restricted Stock Units	Issuer			12700	08/11/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	08/12/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/06/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Adrian G Rawcliffe
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)